[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-364311-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-364311-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","results-comparison-of-cervical-cancer-early-detection-using-cerviray-with-via-test","Results comparison of cervical cancer early detection using cerviray ® with VIA test","","This study investigates the performance of Cerviray AI® against the Cerviray® expert for detecting pre-cancerous cervical lesions, using the Visual Inspection with Acetic Acid (VIA) test as the gold standard. Forty-four patients from health centers in West Java were assessed, comparing sensitivity, specificity, PPV, and ROC AUC. Cerviray AI® showed sensitivity of 42.9%, specificity of 100%, PPV of 100%, and ROC AUC of 71.4%. The expert demonstrated higher sensitivity and ROC AUC, outperforming the AI.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/results-comparison-of-cervical-cancer-early-detection-using-cerviray-with-via-test/364311/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/results-comparison-of-cervical-cancer-early-detection-using-cerviray-with-via-test/364311.png","ImageObject",300,407,{"name":42,"@type":43},"Finn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study’s main objective?","Question",{"text":63,"@type":64},"To compare the performance of Cerviray AI® with the Cerviray® expert for early detection of cervical pre-cancerous lesions, using VIA as the gold standard.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the diagnostic performances evaluated?",{"text":68,"@type":64},"Sensitivity, specificity, PPV, and ROC AUC were compared across Cerviray AI®, the Cerviray® expert, and VIA testing.",{"name":70,"@type":61,"acceptedAnswer":71},"Which approach performed better overall according to ROC AUC?",{"text":72,"@type":64},"The Cerviray® expert outperformed Cerviray AI® in ROC AUC values.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},364311,1790568947,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":102,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Harsono etal. BMC Research Notes (2025) 18:30 [https://doi.org/10.1186/s13104-025-07086-6](https://doi.org/10.1186/s13104-025-07086-6)  \nBMC Research Notes  \nRESEARCH NOTE Open Access  \nResults comparison of cervical cancer early detection using cerviray ® with VIA test  \nAli Budi Harsono 1, Hadi Susiarno 1,2*, Dodi Suardi 1, Kemala Isnainiasih Mantilidewi 1, Viko Duvadilan Wibowo 1 and Yudi Mulyana Hidayat 1  \nAbstract  \nObjectives This study investigates the performance of artificial intelligence (AI) technology, namely Cerviray AI®, compared with Cerviray® expert, aiming to compare its sensitivity, specificity, positive predictive value (PPV), and area under the receiver operating characteristic curve (AUC ROC) . The Visual Inspection with Acetic Acid (VIA) test is used as the gold standard.  \nResults The study involved 44 patients from various health centers in West Java Province. Performance of Cerviray AI®, or Cerviray® expert, and lastly VIA tests were compared in their ability to detect pre-cancerous cervical lesions in high-risk women of childbearing age. The current study indicated that Cerviray AI® had a sensitivity of 42 . 9%, specificity of 100%, PPV of 100%, and ROC AUC values of 71.4% . In comparison, the evaluation of the Cerviray® expert demonstrated a sensitivity of 71 .4%, specificity of 97 . 3%, PPV of 83 . 3%, and ROC AUC values of 84 .4% . In conclusion, the evaluation of Cerviray® expert outperformed Cerviray AI® in ROC AUC values.  \nTrial registration Clinical Trials. gov Identifier NCT06518070 Retrospectively registered.  \nKeywords Cervical cancer, Cerviray, VIA test, Early detection  \nIntroduction  \nCervical cancer is a cancer caused by Human Papilloma Virus (HPV) infection. Cervical cancer is the eighth most common cancer in the world, with an estimated 662,301 new cases and 348,874 deaths in 2022 worldwide, and the prevalence of HPV infection in women was 5.2%.1 About 90% of new cases and deaths from cervical cancer occur in low-and middle-income countries [1].  \n*Correspondence:  \nHadi Susiarno  \n[hadi.susiarno@unpad.ac.id](hadi.susiarno@unpad.ac.id)  \n1Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran–Dr. Hasan Sadikin General Hospital, Bandung, Indonesia  \n2Faculty of Medicine, Universitas Padjadjaran – Dr. Hasan Sadikin General Hospital, Jl. Pasteur No. 38, Bandung, West Java 40161, Indonesia  \nAs the causative agent of almost all cases of cervical cancer, HPV can infect both male and female genital regions, including the skin of the vulva, penis, and anus; the lining of the vagina, cervix, and rectum; and the lining of the mouth and throat [2]. Unlike other sexually transmitted infections, most signs and symptoms of HPV are absent. Therefore, most people are unaware of HPV infection in their bodies. HPV types 16 and 18 are the most oncogenic virus types and are responsible for causing more than 75% of cervical cancer cases and most other genital cancers [3].  \nAs in our body, many viruses like HPV can cause cancer cells because of its persistent infection. The hypoxic condition of cells and oxidative stress can lead to DNA damage and altered nuclear architecture. This condition becomes a transactivator function in virus-infected cells  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to ","cbCaicnOU9oBtpAL","https://ap.wps.com/l/cbCaicnOU9oBtpAL","pdf",925476,"English","# Abstract\n## Objectives\n## Results\n## Trial registration\n# Introduction\n## Etiology and epidemiology of cervical cancer\n## HPV infection and detection rationale\n## Screening strategies and VIA test\n## Role of AI and remote access","[{\"question\":\"What was the study’s main objective?\",\"answer\":\"To compare the performance of Cerviray AI® with the Cerviray® expert for early detection of cervical pre-cancerous lesions, using VIA as the gold standard.\"},{\"question\":\"How were the diagnostic performances evaluated?\",\"answer\":\"Sensitivity, specificity, PPV, and ROC AUC were compared across Cerviray AI®, the Cerviray® expert, and VIA testing.\"},{\"question\":\"Which approach performed better overall according to ROC AUC?\",\"answer\":\"The Cerviray® expert outperformed Cerviray AI® in ROC AUC values.\"}]","Results comparison of cervical cancer early detection using cerviray ® with VIA test | PDF",1790156893,15,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/24af22db4cde84bb22383c9a4b2345fc.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/953f8fe7a9ba6c6ef0f14a09f3d3e3fc.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/569b2403d34635fd4850d4cd6c663973.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e6e16779d337b44938745d4b42bd24dc.webp",980,1306]